133 related articles for article (PubMed ID: 25244542)
1. KRAS and BRAF mutations in anal carcinoma.
Serup-Hansen E; Linnemann D; Høgdall E; Geertsen PF; Havsteen H
APMIS; 2015 Jan; 123(1):53-9. PubMed ID: 25244542
[TBL] [Abstract][Full Text] [Related]
2. Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors.
Bidinotto LT; Véo CA; Loaiza EA; De França AP; Lorenzi AT; Rosa LA; De Oliveira CM; Levi JE; Scapulatempo-Neto C; Longatto-Filho A; Reis RM
Mol Med Rep; 2016 Oct; 14(4):3791-7. PubMed ID: 27573925
[TBL] [Abstract][Full Text] [Related]
3. KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).
Casadei Gardini A; Capelli L; Ulivi P; Giannini M; Freier E; Tamberi S; Scarpi E; Passardi A; Zoli W; Ragazzini A; Amadori D; Frassineti GL
PLoS One; 2014; 9(3):e92071. PubMed ID: 24642661
[TBL] [Abstract][Full Text] [Related]
4. No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status.
Prigge ES; Urban K; Stiegler S; Müller M; Kloor M; Mai S; Ottstadt M; Lohr F; Wenz F; Wagner S; Wittekindt C; Klussmann JP; Hampl M; von Knebel Doeberitz M; Reuschenbach M
Hum Pathol; 2014 Nov; 45(11):2347-54. PubMed ID: 25257576
[TBL] [Abstract][Full Text] [Related]
5. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
6. Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients.
Rako I; Jakic-Razumovic J; Katalinic D; Sertic J; Plestina S
Neoplasma; 2012; 59(4):376-83. PubMed ID: 22489692
[TBL] [Abstract][Full Text] [Related]
7. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
8. KRAS and BRAF mutations in sinonasal cancer.
López F; García Inclán C; Pérez-Escuredo J; Alvarez Marcos C; Scola B; Suárez C; Llorente JL; Hermsen MA
Oral Oncol; 2012 Aug; 48(8):692-7. PubMed ID: 22459936
[TBL] [Abstract][Full Text] [Related]
9. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
10. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.
Kotoula V; Sozopoulos E; Litsiou H; Fanourakis G; Koletsa T; Voutsinas G; Tseleni-Balafouta S; Mitsiades CS; Wellmann A; Mitsiades N
Endocr Relat Cancer; 2009 Jun; 16(2):565-72. PubMed ID: 19190079
[TBL] [Abstract][Full Text] [Related]
12. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
13. KRAS and BRAF mutations in Serbian patients with colorectal cancer.
Jakovljevic K; Malisic E; Cavic M; Krivokuca A; Dobricic J; Jankovic R
J BUON; 2012; 17(3):575-80. PubMed ID: 23033302
[TBL] [Abstract][Full Text] [Related]
14. KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review.
Shigaki H; Baba Y; Watanabe M; Miyake K; Murata A; Iwagami S; Ishimoto T; Iwatsuki M; Yoshida N; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S485-91. PubMed ID: 23274581
[TBL] [Abstract][Full Text] [Related]
15. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.
Van Damme N; Deron P; Van Roy N; Demetter P; Bols A; Van Dorpe J; Baert F; Van Laethem JL; Speleman F; Pauwels P; Peeters M
BMC Cancer; 2010 May; 10():189. PubMed ID: 20459770
[TBL] [Abstract][Full Text] [Related]
17. EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer.
Martin V; Zanellato E; Franzetti-Pellanda A; Molinari F; Movilia A; Paganotti A; Deantonio L; De Dosso S; Assi A; Crippa S; Boldorini R; Mazzucchelli L; Saletti P; Frattini M
Histol Histopathol; 2014 Apr; 29(4):513-21. PubMed ID: 24122611
[TBL] [Abstract][Full Text] [Related]
18. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
Chang YT; Chang MC; Huang KW; Tung CC; Hsu C; Wong JM
J Gastroenterol Hepatol; 2014 May; 29(5):1119-25. PubMed ID: 24372748
[TBL] [Abstract][Full Text] [Related]
20. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]